{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=13&state=Florida", "query": { "state": "Florida", "city": "Jacksonville", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1873, "total_pages": 188, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=14&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=12&state=Florida&page_size=10" }, "source": "local", "last_synced_at": "2026-10-27T17:26:54.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06922591", "title": "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "MTAP Deletion", "NSCLC", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer Metastatic", "RAS Mutation", "Thoracic Cancer" ], "interventions": [ { "name": "RMC-6236", "type": "DRUG" }, { "name": "RMC-9805", "type": "DRUG" }, { "name": "TNG462", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tango Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2025-05-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T14:01:33.301Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06922591" }, { "nct_id": "NCT06604884", "title": "NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Intracranial Aneurysm" ], "interventions": [ { "name": "Treatment of Intracranial Aneurysms", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Neurovascular Clinical Affairs", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 118, "start_date": "2025-12-12", "completion_date": "2033-09", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T18:10:36.383Z", "location_count": 10, "location_summary": "Jacksonville, Florida • Marietta, Georgia • Evanston, Illinois + 7 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Carmel", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06604884" }, { "nct_id": "NCT06419374", "title": "A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis" ], "interventions": [ { "name": "Pegozafermin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1800, "start_date": "2024-05-24", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-27T12:40:47.163Z", "location_count": 150, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06419374" }, { "nct_id": "NCT06318169", "title": "A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis" ], "interventions": [ { "name": "Pegozafermin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1350, "start_date": "2024-03-13", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-27T17:26:54.044Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318169" }, { "nct_id": "NCT06090539", "title": "A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BMS-986458", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Glofitamab/Obinutuzumab", "type": "DRUG" }, { "name": "Golcadomide", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2023-12-29", "completion_date": "2028-10-28", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T06:19:39.159Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090539" }, { "nct_id": "NCT05946213", "title": "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1500, "start_date": "2023-12-14", "completion_date": "2041-03-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T07:06:26.763Z", "location_count": 424, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05946213" }, { "nct_id": "NCT05641688", "title": "[18F]PI-2620 Phase 3 Histopathological Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "[18F]PI-2620", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantheus Biosciences Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 200, "start_date": "2022-12-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T15:21:04.460Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05641688" }, { "nct_id": "NCT05432804", "title": "Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioblastoma, IDH-Wildtype", "Recurrent MGMT-Methylated Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2023-03-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:16:31.601Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432804" }, { "nct_id": "NCT05327686", "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Ablative Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-02-01", "completion_date": "2033-06-15", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T15:21:30.282Z", "location_count": 342, "location_summary": "Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327686" }, { "nct_id": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "ADI-PEG 20", "type": "BIOLOGICAL" }, { "name": "AZD1390", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Paxalisib", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tinostamustine", "type": "DRUG" }, { "name": "Troriluzole", "type": "DRUG" }, { "name": "VAL-083", "type": "DRUG" }, { "name": "VT1021", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2250, "start_date": "2019-07-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T13:09:21.801Z", "location_count": 42, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970447" } ] }